Kerecis Showcases Fish-Skin Graft Data at SAWC Spring

Got story updates? Submit your updates here. ›

Kerecis, a company pioneering the use of sustainably sourced fish-skin in cellular therapy and tissue regeneration, will present new clinical data on the effectiveness of its intact fish-skin grafts for treating severe pressure ulcers at the Symposium on Advanced Wound Care (SAWC) Spring 2026 in Charlotte, North Carolina. The real-world trial found that intact fish-skin demonstrated superior clinical effectiveness when compared with standard care for treating severe, hard-to-heal Stage 3 and 4 pressure ulcers.

Why it matters

Stage 3 and 4 pressure ulcers represent a major burden to patients and the healthcare system. Demonstrating the statistical superiority of intact fish-skin grafts in this complex patient population underscores the vital medical necessity of advanced biologic therapies when standard treatments stall.

The details

The industry-supported symposium will feature clinical insights on real-world applications of fish-skin grafts across complex and atypical wounds, as well as the presentation of the new clinical research. The real-world trial evaluated 80 patients, finding that ulcers treated with intact fish-skin achieved a 49% average percent area reduction, compared to a 34% reduction in the standard of care control group (p=0.0028). Additionally, 67.5% of wounds treated with intact fish-skin were categorized as either "Healed" or "Improved," significantly outpacing the 55.0% success rate observed in the control group (p=0.0379).

• The industry-supported symposium will take place on Thursday, April 9, 2026, from 4:30 PM to 5:30 PM EDT.
• The poster reception featuring 13 abstracts on intact fish-skin technology will be held on Friday, April 10, 2026, from 7:30 PM to 8:30 PM EDT.

What they’re saying